Medtronic MiniMed spin-off oversubscribed: Can MDT maintain its upward momentum?

Traders Union
All News
Stocks
Medtronic jumps 3.3% to $91.39 today

Highlights

Medtronic confirms strong market demand for its MiniMed Group spin-off as the exchange offer was oversubscribed by the October 9, 2026 expiration.
The company reports serving 82 million patients, investing $2.9 billion in R&D, and achieving over 315 product approvals.
Shares of Medtronic trade in a bullish structure with strong upward momentum and are expected to consolidate between $89.47 and $93.31.

Oversubscribed diabetes spin-off boosts sentiment amid innovation signals

Medtronic's recent announcement that its exchange offer for MiniMed Group shares was oversubscribed as of the October 9, 2026 expiration date has driven strong investor interest in the ongoing Diabetes business spin-off, according to Gurufocus. This result confirms the value the market places on the new entity and enhances the focus on Medtronic's remaining core businesses, fueling buying interest in the stock. Additionally, the company reported having served 82 million patients, invested $2.9 billion in R&D, and achieved over 315 product approvals, further supporting a positive operational narrative and underpinning sentiment around its innovation strategy.

Momentum signals diverge as upside stretches above key support

On the technical side, MDT trades above its MA-20 at $87.41 and MA-50 at $87.12 on the hourly chart, while also holding above the MA-200 at $88.38 on the daily chart. Key chart support is found at the Ichimoku Kijun level at $87.61. Momentum indicators signal continued strength: MACD and ADX are both on a buy signal, RSI reads 59.75 in the buy zone, and CCI remains bullish. Notably, Stoch RSI points to a strong sell, which, combined with the overbought reading in Bull/Bear Power, flags that upside may be stretched. The Awesome Oscillator is neutral and does not add directional bias.

Bullish breakout favored as consolidation risk remains low

Looking to the near term, MDT is expected to trade in a range between $89.47 and $93.31. Upside continuation is highly probable, with technical and news flow strongly favoring a consolidation or breakout higher within this band. A bullish scenario would see the price break above resistance and test the upper boundary near $93.31, while a reversal scenario would require sustained selling pressure sufficient to break the Kijun support around $87.61, an outcome currently viewed as unlikely given prevailing signals.

Anton Kharitonov, expert at Traders Union, believes Medtronic’s spin-off news and strong financials have sparked a positive reaction. He sees good momentum on both technical and sentiment factors, but notes some warning signals for overextension. Base case remains for consolidation above $87.61 unless sellers reclaim control. "Despite improving sentiment, I remain cautious and prefer to wait for a confirmed breakout above resistance rather than chase the move here."

Earlier, analysts noted that sector pressures and shifting demand patterns were prompting investors to scrutinize the valuation and growth outlook of defensive stocks across global markets. The latest technical breakout and successful Diabetes business spin-off in Medtronic add a new dimension, with traders now monitoring $93.31 as the key upside level over the near term.

Source of Data: MDT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.